ANTA Sports Completes Acquisition of 29.06% Stake in PUMA, Becomes Largest Shareholder
Original HTML

ANTA Sports Completes Acquisition of 29.06% Stake in PUMA, Becomes Largest Shareholder

- Becomes PUMA's largest shareholder, further strengthening ANTA Sports' globalization strategy

- Will support unlocking PUMA's potential across global markets including China, leveraging complementary strengths and multi-brand management experience

- Fully respects PUMA's deep sports heritage, distinctive brand identity and corporate culture, as well as its independent governance and brand autonomy

HONG KONG, Oct. 7, 2026 /PRNewswire/ -- ANTA Sports Products Limited, the world's leading multi-brand sportswear group ("ANTA Sports", stock codes: 2020 (HKD counter) and 82020 (RMB counter), and its subsidiaries collectively the "ANTA Group" or the "Group"), today announced the completion of its acquisition of a 29.06% stake in PUMA SE from Artémis SAS, the investment company of the Pinault family, for EUR 1,505.5 million in cash. Following the receipt of all relevant regulatory approvals and the fulfillment of customary closing conditions, ANTA Sports is now the largest shareholder of PUMA.

For ANTA Sports, this investment marks a major milestone in executing its "single-focus, multi-brand, globalization" strategy and strengthening the Group's international profile, reach and competitiveness in the global sporting goods market. ANTA Sports will bring expertise to PUMA that the Group has built across multiple brands over the years, including management, retail, and global resource integration capabilities.

Ding Shizhong, Board Chairman of ANTA Sports, commented: "We are delighted to become PUMA's largest shareholder and a long-term strategic partner. The global sporting goods market continues to offer significant growth opportunities as more people embrace active lifestyles and increase their participation in sports. ANTA Sports has built its success on a multi-brand strategy. We believe the value of a multi-brand group lies in helping each brand realize its full potential by leveraging the capabilities and resources of the broader group. PUMA has a rich heritage and strong underlying brand value. We have confidence in its management team and support the strategic transformation currently underway. As a long-term shareholder, we look forward to sharing our experience and capabilities, particularly in retail and operations, while respecting PUMA's independence and brand identity. Our ambition is to support PUMA in realizing its full potential and creating lasting value for consumers around the world."

"PUMA has built one of the most recognized sports brands in the world, with a rich heritage, a deep sports credibility, a global footprint, leading innovations and strong partners. We welcome ANTA Sports as PUMA's largest shareholder and view its long-term commitment as a strong vote of confidence in our strategy, our management team and our future," said Arthur Hoeld, CEO of PUMA SE. "We look forward to building a fruitful relationship and exploring areas where our respective strengths can create sustainable value for PUMA and its shareholders on our journey to become a top 3 global sports brand."

ANTA Sports fully respects PUMA's sport heritage, distinctive brand identity and corporate culture, as well as its independent governance and brand autonomy. As previously announced, the Group will seek adequate representation on PUMA's Supervisory Board. The Group currently has no plans to make a takeover offer for PUMA.

For further information, please contact:

Media Contact

Danielle Berg, US/international, +1 214 7092300, [email protected]

Claudia Kosser, Germany, +49 162 2737953, [email protected]

Louis Hung, APAC, +852 90841801, [email protected]

Investor Contact

ANTA Sports Products Limited

Investor Relations Department

Tel:    (852) 2116 1660 

Fax:    (852) 2116 1590 

E-mail: [email protected]

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302901071
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET refers to the 29.06% stake as a 'controlling stake', but the SOURCE only describes ANTA as 'largest shareholder' and does not characterize the stake as controlling. This is an unsupported material factual claim.
Source Name
Unknown Company
Original Summary

<p>Becomes PUMA's largest shareholder, further strengthening ANTA Sports' globalization strategy Will support unlocking PUMA's potential across global markets including China, leveraging complementary strengths and multi-brand management experience Fully respects PUMA's deep sports heritage,...</p>

Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "ANTA Sports Finalizes EUR1.5B Deal, Becomes PUMA's Top Shareholder", "body_html": "<p><strong>Hong Kong -- [CURRENT_DATE] --</strong> ANTA Sports Products Limited has completed its acquisition of a 29.06% stake in PUMA SE from Artémis SAS, the investment vehicle of the Pinault family, for EUR 1,505.5 million in cash, making the Hong Kong-listed group PUMA's largest shareholder.</p><h5>ANTA Sports secures largest shareholder position after regulatory clearance</h5><p>The transaction closed following receipt of all relevant regulatory approvals and fulfillment of customary closing conditions. ANTA Sports (stock codes: 2020 and 82020) now holds the controlling stake previously owned by Artémis SAS, the Pinault family's investment company.</p><h5>Group plans board representation but rules out takeover offer</h5><p>ANTA Sports confirmed it will seek adequate representation on PUMA's Supervisory Board. The Group stated it currently has no plans to make a takeover offer for PUMA, and said it will respect PUMA's independent governance, brand autonomy, sports heritage and corporate culture.</p><h5>Chairman frames deal as milestone in global multi-brand strategy</h5><p>Ding Shizhong, Board Chairman of ANTA Sports, said the acquisition marks a major milestone in executing the Group's \"single-focus, multi-brand, globalization\" strategy. He said ANTA Sports intends to share its retail and operations experience with PUMA while respecting the brand's independence, adding that the Group has confidence in PUMA's management team and supports its ongoing strategic transformation.</p><h5>PUMA CEO calls investment a vote of confidence in current strategy</h5><p>Arthur Hoeld, CEO of PUMA SE, welcomed ANTA Sports as the largest shareholder, characterizing the long-term commitment as confidence in PUMA's strategy and management team. Hoeld said the two companies will explore areas where their respective strengths can create sustainable value as PUMA pursues its goal of becoming a top 3 global sports brand.</p><p>ANTA Sports said it will leverage complementary strengths and its multi-brand management experience to support PUMA's growth across global markets, including China.</p>", "meta_description": "ANTA Sports closes EUR1.5B acquisition of 29.06% PUMA stake from Artémis SAS, becoming largest shareholder and seeking board representation.", "seo_keywords": "ANTA Sports, PUMA SE, Artémis SAS, sportswear M&A, largest shareholder, multi-brand strategy, Hong Kong stock exchange", "companies": ["ANTA Sports", "PUMA SE", "Artémis SAS"], "industries": ["Retail & Consumer Goods Industry"], "markets_regions": ["Global", "Europe", "China"], "news_type": ["financial_disclosure", "general_news"], "themes": ["mergers_and_acquisitions", "globalization"], "products": [], "events": [], "cta_text": "Follow further developments on ANTA Sports' shareholder role and strategic influence at PUMA.", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
3d7c0a6db59d9471b2b0af1d955b9a71
Segway Expands Global Omni-Channel Network With New Models and Real Range Standard
Image File
Original HTML

Segway Expands Global Omni-Channel Network With New Models and Real Range Standard

New all-terrain and long-range e-scooters — ZT3 MAX and MAX G3 Pro — debut as Segway scales up worldwide sales and service alongside the "Range at Max. Speed" testing protocol.

COLOGNE, Germany and PARIS, Oct. 7, 2026 /PRNewswire/ -- Segway, the global leader in innovative personal transportation and service robotics, today announced at simultaneous launch events in Cologne and Paris an expansion of its global omni-channel sales and service network alongside two new models, the ZT3 MAX and MAX G3 Pro.

A further launch event in Barcelona later this month extends the European launch. Built on Segway's proven ZT and MAX G series, the new models enrich Segway's premium lineup.

Built for the Way People Actually Ride

Segway's new premium models address the two most common e-scooter complaints: range figures that don't match real-world use, and handling confidence that falls short for daily riding. The two new models target two key use cases:

ZT3 MAX: All-Terrain Confidence

Built for demanding urban roads and mixed terrain, the ZT3 MAX combines all-terrain capability with Segway's new ICBS (Intelligent Combined Braking System) for smoother, more confident stopping on uneven surfaces.

MAX G3 Pro: Long-Range Daily Commuting

Built for longer daily journeys, the MAX G3 Pro pairs a high-capacity battery with built-in fast charging, delivering comfortable, stable long-distance rides.

Real Range: What You See Is What You Ride

For e-scooter buyers, advertised range is often the first indicator of whether a product can meet daily travel needs without frequent charging.

Segway's Real Range standard builds on TÜV's "Range at Max. Speed" testing protocol. Instead of idealized conditions, it tests every mode at full speed until the scooter slows to 60% of the maximum. Segway will apply this standard across its new premium lineup and future generations and call for industry-wide adoption of standardized, real-world range labeling.

Powered by Segway's proprietary SegRange™ efficiency technology, real-world range is 60–72 km (ZT3 MAX) and 80–100 km (MAX G3 Pro), varying by local speed regulations across markets.

Global Omni-Channel Sales and Service Network

Segway is expanding its global omni-channel network to make e-scooters easier to buy, repair and own. Three complementary channels — national retail partners, specialist dealers offering test rides and local repairs, and official online channels — provide consistent, reliable support however riders choose to purchase.

In Europe, Segway plans to build a network of 1,000 specialist dealer partners over the next five years — including Segway Service Dealers — while rolling out a self-repair program across Europe and Asia-Pacific, building on its US model, where 65% of common repairs are completed by users at home.

"As e-scooters evolve into daily transport, riders around the world deserve products that work as promised, and service that supports them long after purchase," said Johnny Zhang, Vice President of Segway Micromobility Business Group. "These new models are made for real daily riding, with range numbers measured on real roads, and support that doesn't leave you stranded."

Availability

Europe: ZT3 MAX and MAX G3 Pro will be available from November — in Germany (20 km/h D-version, eKFV-compliant) and in France and Spain (25 km/h E-version models). Region-specific pricing will be announced closer to sales start.

United States: MAX G3 Plus is available for purchase with an MSRP of $1,499.99 at store.segway.com as well as trusted retailers including Amazon and Best Buy.

Asia Pacific: The ZT3, another version of the all-terrain ZT flagship series, will roll out progressively across multiple countries within 2026. Product availability and pricing will be communicated locally at launch.

About Segway

Segway transformed micromobility in 1999 with the revolutionary Personal Transporter, igniting global curiosity about the future of personal transportation. With a mission of "Simply Moving", Segway is dedicated to simplifying how people and goods move, improving efficiency, and enhancing the overall experience of everyday life.

For decades, Segway has continuously set new benchmarks in short-distance transportation and consumer robotics, constantly pushing the boundaries of innovation. Today, as the global leader in innovative personal transportation and service robotics, Segway's offerings have evolved far beyond its origins. From eKickScooters and GoKarts to e-bikes, powersports vehicles, and personal robots, Segway is pioneering the future of mobility with breakthrough technology, delivering innovative products that redefine the way we move. Discover more at www.segway.com.

SOURCE Segway

Share this article

Class (B2B/B2C)
B2C
Ingest Status
Rewritten
Dedupe hash
prn_302900961
Press Eligible
Yes
Press Eligible Reason
Consumer e-scooter product launch and expansion of Segway’s sales and service network.
Source Name
Unknown Company
Original Summary

<p>New all-terrain and long-range e-scooters — ZT3 MAX and MAX G3 Pro — debut as Segway scales up worldwide sales and service alongside the "Range at Max. Speed" testing protocol. COLOGNE, Germany and PARIS, Oct. 7, 2026 /PRNewswire/ -- Segway, the global leader in innovative personal...</p>

Image URL
https://mmx.prnewswire.com/media/MS1999643/20260930065125EDT_image_1.jpg?id=OA2979428&p=facebook
Content Hash (SHA-256, erste 32 hex)
59be5a0611f1defd9a71766f6c28d3a5
AGCO Announces Third-Quarter 2026 Earnings Release and Conference Call
Image File
Original HTML

DULUTH, Ga., Oct. 7, 2026 /PRNewswire/ -- AGCO (NYSE: AGCO) today announced its third-quarter 2026 earnings release conference call is scheduled for Thursday, October 29, at 10 a.m. ET. The company will refer to slides on its conference call. Interested persons can access the conference call and slide presentation via AGCO's website at www.agcocorp.com under the "Investors" Section. The webcast will also be archived immediately afterward for 12 months.

About AGCO

AGCO (NYSE: AGCO) is a global leader in agricultural machinery and precision agriculture technologies. Driven by a Farmer-First strategy, AGCO delivers value through its differentiated leading brands, Fendt™, Massey Ferguson™, PTx™ and Valtra™.  AGCO's high-performance equipment and smart farming solutions, including brand-agnostic retrofit technologies and autonomous offerings, empower farmers to drive productivity while sustainably feeding the world. For more information, visit www.agcocorp.com.  

Additional AGCO News

- AGCO Tech Day 2026 Spotlights Autonomy, AI and Mixed-Fleet Solutions to Enhance Farmer Profitability

- AGCO Restructures Executive Leadership Team

- AGCO to Unveil Global Products and Farmer-First Innovations at 2026 Farm Progress Show

SOURCE AGCO Corporation

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302899697
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): Final paragraph is a generic 'About the Company' boilerplate describing AGCO's brand portfolio and product areas, with no news context, instead of ending with event-specific information.
Source Name
Unknown Company
Original Summary

<p>DULUTH, Ga., Oct. 7, 2026 /PRNewswire/ -- AGCO (NYSE: AGCO) today announced its third-quarter 2026 earnings release conference call is scheduled for Thursday, October 29, at 10 a.m. ET. The company will refer to slides on its conference call. Interested persons can access the conference...</p>

Image URL
https://mmx.prnewswire.com/media/MS2001931/AGCO-IR-Release-Image-Q3-Earnings-Newsroom-Thumbnail.jpg?id=OA2985751&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "AGCO Sets Oct. 29 Date for Q3 2026 Earnings Call", "body_html": "<p><strong>Duluth, Ga. -- [CURRENT_DATE] --</strong> AGCO Corporation (NYSE: AGCO) will hold its third-quarter 2026 earnings conference call on Thursday, October 29, at 10 a.m. ET.</p><h5>AGCO schedules Q3 2026 results briefing for October 29</h5><p>The agricultural machinery maker confirmed the call will include a slide presentation, accessible via the \"Investors\" section of AGCO's website. The webcast will remain archived on the site for 12 months following the live event.</p><p>AGCO's brand portfolio includes Fendt, Massey Ferguson, PTx and Valtra, spanning precision agriculture technology and autonomous farming equipment.</p>", "meta_description": "AGCO Corporation will host its Q3 2026 earnings conference call on October 29 at 10 a.m. ET, with a slide presentation archived online for 12 months.", "seo_keywords": "AGCO, Q3 2026 earnings, agricultural machinery, precision agriculture, investor call, NYSE AGCO, Fendt, Massey Ferguson, Valtra", "companies": ["AGCO Corporation"], "industries": ["Agriculture & Food Production"], "markets_regions": ["United States"], "news_type": ["financial_disclosure"], "products": [], "themes": ["financial_disclosure"], "events": ["Q3 2026 Earnings Conference Call"], "cta_text": "Investors can access the earnings call and slide presentation via AGCO's website under the Investors section.", "learn_more": "http://www.agcocorp.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
fa63b85de56bfb68ae45f8b158af04a4
Secondhand Is Now the Norm: 76% of Americans Bought Used Last Year
Image File
Original HTML

The Consumer Collective's "Second Nature" study finds nearly half of Americans already buy or would consider buying luxury items used, and close to 9 in 10 have bought secondhand at some point.

BROOKLYN, N.Y., Oct. 7, 2026 /PRNewswire/ -- Secondhand shopping has moved well past thrift-store clothing. The Consumer Collective, a consumer insights and advisory firm, today released "Second Nature: The State of Secondhand Shopping in America," a report on how U.S. consumers shop, spend and think about buying used goods.

Key findings

- 76% bought something secondhand in the past 12 months, and 89% have done so at some point

- 44% are buying more secondhand than they did two years ago, including 66% of Gen Z

- 49% already buy luxury items secondhand or would consider it, rising to nearly 80% once shoppers still on the fence are counted

- Millennials (89%) and Gen Z (85%) lead in secondhand buying in the past year, versus 59% of Americans 62 and older

Luxury resale shows the clearest room to grow, led by younger shoppers: 61% of Gen Z and 60% of Millennials already buy luxury items used or would consider it, compared with 27% of those 62 and older. Condition and authenticity top the list of concerns about buying luxury used.

Clothing remains the entry point — 71% of shoppers have bought used clothing — but for the next year, consumer shopping plans extend into furniture, electronics and books. Few shoppers assume new means better. Just 11% said brand-new offers better value; 34% said secondhand does and half said it depends on the category.

In-person shopping still wins out over online: 54% of consumers prefer buying secondhand in a physical store, 18% prefer online and 28% like both equally. Shoppers who like both spend the most, with about 1 in 3 spending $500 or more on secondhand goods in the past year. Thrift stores remain the single most popular destination.

"Enthusiasm around secondhand shopping started in clothes, but is spreading to more categories," said Allison Collins, co-founder of The Consumer Collective. "Brands that treat resale as a side market are missing where their customers already shop."

"The growth of the resale market has massive cross-category implications," said Jessica Ramírez, co-founder of The Consumer Collective. "Over time, we expect to see consumers' gravitation towards secondhand pull spend from other retailers."

The full report includes results of an August survey of 400 U.S. shoppers, category breakdowns, motivations, generational and income data, and a regional look at where secondhand shopping is the most popular.

"Second Nature" is available now through The Consumer Collective's insights library. More data is available to media upon request.

About The Consumer Collective

The Consumer Collective is a consumer insights and advisory firm helping brands, founders, investors and technology companies navigate a rapidly changing consumer landscape. We connect the dots between how people live, think and spend and what those shifts mean for business. Our work brings together original consumer research, market intelligence, trend forecasting and deep sector expertise to identify emerging opportunities and separate lasting shifts from passing signals. From beauty and wellness to fashion, food, retail and technology, we help clients understand what is changing, decide where to focus and turn consumer insight into clear, actionable business strategy. Founded by Allison Collins and Jessica Ramírez, The Consumer Collective also publishes Inside The Collective, a paid weekly newsletter.

Media Contact: [email protected] | theconsumercollective.co

SOURCE The Consumer Collective

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900478
Press Eligible
Yes
Press Eligible Reason
Consumer research on secondhand shopping trends and their implications for brands and retailers.
Source Name
Secondhand Is Now the Norm
Original Summary

<p>The Consumer Collective's "Second Nature" study finds nearly half of Americans already buy or would consider buying luxury items used, and close to 9 in 10 have bought secondhand at some point. BROOKLYN, N.Y., Oct. 7, 2026 /PRNewswire/ -- Secondhand shopping has moved well past...</p>

Image URL
https://mmx.prnewswire.com/media/MS1977106/TCC_Logo_Green.jpg?id=OA2984008&p=facebook
Content Hash (SHA-256, erste 32 hex)
60b1f88ea93ab694b4075955a8655ba9
U.S. Department of Veterans Affairs Selects CLEAR for New Pilot Initiative to Modernize the Veteran Experience on VA.gov
Image File
Original HTML

First-of-its-kind effort to close the gap between the benefits Veterans have earned and the benefits they receive

NEW YORK, Oct. 7, 2026 /PRNewswire/ -- CLEAR (NYSE: YOU), the secure identity company, announced today that the U.S. Department of Veterans Affairs (VA) has integrated CLEAR1, CLEAR's secure identity platform, as part of a pilot to reimagine the Veteran experience across digital and physical touchpoints. The pilot provides a new, fast, simple, and secure way for Veterans to create or access their VA.gov account—online or in person at select VA Medical Centers.

VA serves a community of roughly 17 million living U.S. Veterans and operates the nation's largest integrated health care system, serving 9.1 million enrolled Veterans each year. VA.gov is the critical digital connection to the care, benefits and services Veterans have earned, but that connection begins with the ability to create and access a VA.gov account. As part of VA's broader modernization effort, the CLEAR1 pilot will make that first step simpler and more consistent, whether a Veteran begins online or at a VA facility.

Beginning today, Veterans can select CLEAR to create or access their VA.gov account. After a quick, one-time setup, future sign-ins take just seconds with a selfie. Veterans who prefer in-person support, do not have a smartphone, or face connectivity challenges can enroll with CLEAR Ambassadors using CLEAR Pods at six participating VA medical centers in Brooklyn, New York; Washington, D.C.; Palo Alto, California; Decatur, Georgia; Orlando, Florida; and San Juan, Puerto Rico.

Behind that experience, CLEAR1 uses multi-layered verification that combines biometrics, government-issued identification and trusted data sources to establish confidence in the person accessing the account. That assurance is increasingly important to combat fraud, waste, and abuse among benefit access. Federal agencies reported an estimated $186 billion in improper payments in fiscal year 2025 across 64 programs. At VA, the Government Accountability Office found that the Beneficiary Travel Program alone accumulated an estimated $1 billion in improper payments between 2018 and 2024, including confirmed cases of fraud. Verifying that the right person is receiving the right benefit is the first line of defense, and every dollar recovered is a dollar available to the roughly 17 million Veterans who deserve support and resources after their service.

In anticipation of the pilot's launch, CLEAR invited Veterans to test CLEAR's VA.gov sign-in experience and provide feedback. Cheffren C., a U.S. Army Veteran said: "My transition from military service to civilian life was tough, and the VA has been supportive of me as a veteran all along the way. I see the VA investing in this new technology with CLEAR, and that it's only going to bring these benefits to veterans and their families faster and easier. It's comforting to know the same technology and company I trust from travel is available for veterans accessing VA benefits."

"I use VA.gov for health care, and when I was first separating, I was logging into the website basically every week," said Erik B., a U.S. Navy Veteran who also tested CLEAR on VA.gov. "The sign-in experience with CLEAR is very easy to use. I had assumed there would be more steps or paperwork needed, so I was very impressed with how quick and easy it was. Often when signing in to systems, you have to keep track of different usernames and passwords. What I love about CLEAR is that all goes away. It's a much more seamless process."

Caryn Seidman Becker, CEO of CLEAR, said: "CLEAR's mission is to make experiences safer and easier by securely connecting people to their true identity. We're honored to work with the Department of Veterans Affairs to meet America's Veterans and their loved ones where they are. Veterans earned these benefits, it should be easy for them to access them. Secure identity is the front door to care, and when that door works seamlessly and securely, Veterans get served faster and taxpayer dollars go where they belong."

Verifying with CLEAR is free and optional. Veterans may continue using another sign-in method if they prefer, and choosing not to enroll will not affect their ability to access VA benefits or services. Veterans' personal health information will remain with VA; CLEAR does not receive or access it through the identity verification process.

CLEAR has spent more than 16 years building identity infrastructure for the most highly regulated, highest-stakes environments in the country, from airport security checkpoints to health care. With over 43 million members, CLEAR is the leader in secure identity for the moments that matter most.

CLEAR1 is being deployed across federal health and civilian agencies, and CLEAR is under contract with the Centers for Medicare & Medicaid Services to modernize identity verification on Medicare.gov. CLEAR1 is Full Service certified by Kantara Initiative for NIST IAL2/AAL2 for its standard remote, self-service enrollment flow.

CLEAR is committed to privacy done right. Members are always in control of their own information, and the company does not sell biometric or sensitive personal data. There is no cost for Veterans to use CLEAR to sign in to VA.gov, enrollment is voluntary, and Veterans who choose not to enroll will continue to be served through existing VA processes. The VA and CLEAR will consider expanding this offering pending the results of this pilot program.

About CLEAR

The mission of CLEAR, the secure identity company, is to strengthen security and create frictionless experiences. With over 43 million Members and a growing network of partners across the world, CLEAR's secure identity platform is transforming the way people live, work, and travel. Whether you are traveling, at the stadium, or on your phone, CLEAR connects you to the things that make you, you—making everyday experiences easier, more secure, and friction-free. CLEAR is committed to privacy done right. Members are always in control of their own information, and we do not sell biometric or sensitive personal data. For more information, visit clearme.com.

Forward-Looking Statements

This release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes, without limitation, statements regarding the scope, duration, timing, and potential expansion of the CLEAR1 pilot with the U.S. Department of Veterans Affairs (VA), including the availability of online and in-person enrollment and participating VA medical centers; the expected benefits of the pilot for Veterans, including faster and simpler account creation and access on VA.gov; the deployment of CLEAR1 across federal health and civilian agencies, including under CLEAR's contract with the Centers for Medicare & Medicaid Services; the ability of CLEAR's identity verification technology to help combat fraud, waste, and abuse in federal benefit programs; and anticipated demand for CLEAR's secure identity platform in government and healthcare settings. Investors are cautioned that such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors, including the risk that the VA pilot may not be continued, expanded, or converted into a long-term contract; the risk that Veterans may not adopt CLEAR1 at anticipated rates, including because enrollment is voluntary, or that the pilot may not deliver the expected benefits; reliance on government procurement processes, funding, appropriations (including the risk of a government shutdown), and policy decisions; the ability of government customers to terminate, modify, or decline to renew contracts or pilots, including for convenience; the ability to maintain required certifications and regulatory compliance, including Kantara Initiative Full Service certification for NIST IAL2/AAL2; risks related to the collection, storage, and processing of biometric and personal data; competition in the identity verification market; the ability to successfully deploy CLEAR1 technology at scale across federal agencies; and those described in Clear Secure, Inc.'s filings with the Securities and Exchange Commission, including the sections titled "Risk Factors" in its Annual Report on Form 10-K. Forward-looking statements speak only as of the date of this release, and CLEAR disclaims any obligation to update any forward-looking statements contained herein except as required by law.

Media Contact: [email protected]

SOURCE CLEAR

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900511
Press Eligible
Yes
Press Eligible Reason
Company and technology news about CLEAR providing identity verification for a VA modernization pilot.
Source Name
Unknown Company
Original Summary

<p>First-of-its-kind effort to close the gap between the benefits Veterans have earned and the benefits they receive NEW YORK, Oct. 7, 2026 /PRNewswire/ -- CLEAR (NYSE: YOU), the secure identity company, announced today that the U.S. Department of Veterans Affairs (VA) has integrated CLEAR1,...</p>

Image URL
https://mmx.prnewswire.com/media/MS1245156/CLEAR-Logo.jpg?id=OA2991129&p=facebook
Content Hash (SHA-256, erste 32 hex)
e565d3153ad827f8931c02f84aa14394
Elsevier and JAMA Network sign strategic content agreement for ClinicalKey AI
Image File
Original HTML

Full-text content and visuals from the JAMA Network will inform answers delivered through ClinicalKey AI

NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Elsevier, a global leader in advanced information and analytics, today announced a strategic content agreement with the JAMA Network that brings full-text content and visuals from the JAMA Network Family of Journals to ClinicalKey AI, the company's clinical grade AI workspace. The addition of the JAMA Network's specialty journals further deepens a content collection that already spans leading journals and medical society publications worldwide, giving clinicians full-text access to more than half of the world's top 100 medical journals.

Under the agreement, all published full-text content and visuals from 13 journals — including JAMA, JAMA Network Open and 11 specialty journals (JAMA Cardiology, JAMA Dermatology, JAMA Health Forum, JAMA Internal Medicine, JAMA Neurology, JAMA Oncology, JAMA Ophthalmology, JAMA Otolaryngology–Head & Neck Surgery, JAMA Pediatrics, JAMA Psychiatry and JAMA Surgery) — will inform the responses clinicians receive through ClinicalKey AI.

Clinicians face growing volumes of published evidence and reduced time in which to apply clinical insights. ClinicalKey AI is designed to close that gap by grounding every answer in peer-reviewed, evidence-based sources and linking clinicians directly to the full-text articles behind it.

Omry Bigger, President, Clinical Solutions, Elsevier, said: "Clinicians tell us that trust is the deciding factor in whether they will use AI at the point of care. This strategic content agreement with the JAMA Network means that when a clinician uses ClinicalKey AI, the answer can draw on many years of prestigious evidence-based content from JAMA journals without compromising privacy and security. We look forward to our strong collaboration with the JAMA Network and bringing the best insights and clinical content directly into the hands of clinicians at the point of care."

Brian Shields, Group Vice President and Publisher of JAMA and the JAMA Network said: "The research published across the JAMA Network is intended to help inform clinical decisions at the bedside, in the clinic and in the exam room, Working with a global information and analytics leader like Elsevier extends the reach of that evidence to clinicians in the moments they need it most, with the full article always a click away so they can see the study, the methods and the context behind any answer."

Built for health systems

ClinicalKey AI is deployed by health systems that require both credible content, precision AI and enterprise-grade technology. Access to JAMA Network journals and other evidence-based information is delivered securely and compliantly, with capabilities including:

- API-based integration options, including compatibility with existing workflow tools.

- Support for HIPAA-compliant use in North America, with privacy and security controls built to help protect patient health information (PHI).

- A new deep research assistant that allows clinicians to take a deeper dive into clinical topics.

- Multi-language support and prompt sharing.

- Coming soon: Following the recent acquisition of WellSheet, ClinicalKey AI will offer deeper integration into hospital systems' electronic health records to deliver patient context and trusted clinical information to clinicians.

Content from the JAMA Network journals is available to ClinicalKey AI customers now.

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals, and educators across 170 countries in their vital work. We help impact makers achieve better outcomes with research and clinical-grade solutions built on the world's leading evidence-based scientific and medical content, precision AI, and expert human assessment. We champion inclusion and sustainability, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @elsevierconnect.

SOURCE Elsevier Limited

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302899585
Press Eligible
Yes
Press Eligible Reason
Healthcare AI content partnership for clinical professionals and health systems.
Source Name
Unknown Company
Original Summary

<p>Full-text content and visuals from the JAMA Network will inform answers delivered through ClinicalKey AI NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Elsevier, a global leader in advanced information and analytics, today announced a strategic content agreement with the JAMA Network that brings...</p>

Image URL
https://mmx.prnewswire.com/media/MS1684339/Elsevier-Stacked-Logo-VitalOrange-RGB-NEW.jpg?id=OA2989546&p=facebook
Content Hash (SHA-256, erste 32 hex)
afbf6d89db90491583ed197b66cfc457
Institute for Molecular Medicine and Nuravax Announce First Participants Dosed in Phase 1 TAURUS-1980 Study of AV-1980R
Image File
Original HTML

Groundbreaking randomized study will evaluate safety, tolerability, and immune responses to the investigational preventive tau vaccine in up to 48 cognitively unimpaired individuals with confirmed brain amyloid pathology who are at risk of Alzheimer's.

ORANGE COUNTY, Calif., Oct. 7, 2026 /PRNewswire/ -- The Institute for Molecular Medicine (IMM) and Nuravax today announced that the first four participants have been dosed in TAURUS-1980, a Phase 1 trial of AV-1980R. This is the world's first active immunotherapy targeting pathological tau, whose accumulation in the brain correlates with all stages of Alzheimer's disease.

AV-1980R is a recombinant protein vaccine based on IMM 's universal MultiTEP platform. It is designed to generate helper T-cell responses to non-self MultiTEP epitopes that support B-cell production of antibodies against an N-terminal tau epitope encompassing the phosphatase-activating domain (PAD).

TAURUS-1980 is a multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study. Up to 48 cognitively unimpaired adults aged 65 to 80 with biomarker evidence of amyloid pathology will be randomized 3:1 to AV-1980R or placebo across three ascending-dose cohorts of 20 micrograms, 60 micrograms, and 180 micrograms. Participants receive intramuscular injections at Weeks 0, 4, 38, and are followed through Week 58. The primary objective is safety and tolerability; secondary objectives assess anti-tau antibody and T-cell responses. Exploratory assessments include plasma Alzheimer disease biomarkers, tau PET imaging, and cognitive measures.

"This study asks a focused Phase 1 question: can active tau vaccination be given safely and generate the intended immune response before cognitive symptoms emerge?" said Lon S. Schneider, M.D., a principal investigator at the Keck School of Medicine of USC. "To our knowledge, TAURUS-1980 is the first clinical study of an active tau vaccine in preclinical Alzheimer's disease. If the results support further development, later trials can test effects on biomarkers and clinical progression."

IMM sponsors the trial, which is supported by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), through a $24.5 million grant program AG092924. The study is being conducted under U.S. Food and Drug Administration Investigational New Drug application (IND) 29644 and is registered at ClinicalTrials.gov as NCT07158905.

"Dosing the sentinel cohort marks an important clinical milestone for AV-1980R and the MultiTEP platform," said Michael G. Agadjanyan, Ph.D., contact principal investigator of the NIH-supported program, professor of Immunology at IMM, and co-inventor of AV-1980R. "The safety and immunogenicity data from TAURUS-1980 are intended to guide the design of larger proof-of-concept preventive efficacy studies in preclinical Alzheimer's disease individuals who are at risk of dementia."

About the Institute for Molecular Medicine

The Institute for Molecular Medicine is a nonprofit biomedical research institute developing vaccines and immunotherapies for neurodegenerative diseases and other age-related disorders. IMM developed AV-1980R and the MultiTEP platform and sponsors TAURUS-1980 in collaboration with academic and clinical research partners.

About Nuravax

Nuravax is an IMM spinout biotechnology company advancing active immunotherapies for neurodegenerative diseases. Nuravax holds an exclusive license from IMM covering AV-1980R and the broader MultiTEP-based neurodegenerative vaccine portfolio and is pursuing strategic development and commercialization partnerships. For more information, visit www.nuravax.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the development and potential of AV-1980R and the MultiTEP platform. Such statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. AV-1980R is investigational: its safety and efficacy have not been established, and the U.S. Food and Drug Administration or any other regulatory authority has not approved it.

SOURCE Institute for Molecular Medicine

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900400
Press Eligible
Yes
Press Eligible Reason
Biotechnology companies announce dosing in a Phase 1 Alzheimer’s vaccine trial.
Source Name
Unknown Company
Original Summary

<p>Groundbreaking randomized study will evaluate safety, tolerability, and immune responses to the investigational preventive tau vaccine in up to 48 cognitively unimpaired individuals with confirmed brain amyloid pathology who are at risk of Alzheimer's. ORANGE COUNTY, Calif., Oct. 7, 2026...</p>

Image URL
https://mmx.prnewswire.com/media/MS2003887/IMM-logo.jpg?id=OA2977807&p=facebook
Content Hash (SHA-256, erste 32 hex)
4b8402ce85f1f9ca5b6d7b94da1cde39
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Image File
Original HTML

Intravesical administration of the Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group.

SARASOTA, Fla., Oct. 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive preclinical data in urinary tract infection (UTI) and pulmonary infection indications in animal models treated with Bisphosphocin® compounds.

In an animal model of UTI, intravesical administration of the Bisphosphocin® compound Nu-8 in rodents infected with E. coli resulted in up to 97% inhibition of E. coli growth with a 10% solution compared to no effect in a vehicle control group. In addition, the Bisphosphocin® class has demonstrated in vitro activity against a broad range of resistant bacteria, including those frequently found in UTI such as E. coli, K. pneumoniae, and P. aeruginosa, and has also demonstrated activity against biofilm-forming organisms. Complicated UTIs, especially catheter-associated urinary tract infections (CAUTI), are frequently caused by drug-resistant bacteria and bacterial biofilm.

Bisphosphocin® compounds, when administered as an aerosol formulation, have also demonstrated in vivo activity in animal models of pulmonary infections caused by Acinetobacter species, P. aeruginosa, and A. fumigatus. Additionally, the Bisphosphocin® class has demonstrated in vitro activity against a broad range of resistant bacteria frequently found in pulmonary infections such as H. influenzae, K. pneumoniae, and P. aeruginosa.

Pulmonary infections, such as community acquired bronchial pneumonia (CABP), hospital acquired bronchial pneumonia (HABP), and ventilator acquired bronchial pneumonia (VABP), are frequently caused by drug resistant bacteria. In addition, patients with cystic fibrosis have recurrent bacterial and fungal lung infections with organisms such as P. aeruginosa and A. fumigatus.

"We continue to be encouraged by the performance of different members of the Bisphosphocin® class of compounds when tested against various bacterial species, which are known to have a major impact on human health and are key contributors to the AMR crisis," said Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics. "The Bisphosphocin® class of compounds possesses key characteristics including rapid and potent antimicrobial action and broad-spectrum activity with no expected resistance development, which could make them valuable assets in fighting the AMR crisis. We look forward to continuing development of the various Bisphosphocin® compounds to identify the most suitable candidate to be advanced into early clinical development."

Lakewood-Amedex Biotherapeutics' lead Bisphosphocin® candidate, Nu-3 formulated as a topical gel, is being studied in an ongoing Phase 2a trial of mildly infected diabetic foot ulcers (iDFU), with topline data expected in the first quarter of 2027.

About Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, the potential of Bisphosphocin® compounds in urinary tract and pulmonary infection indications, plans to identify and advance a candidate into clinical development, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results, including results in animal models or in vitro studies, may not be predictive of future results or replicated in humans; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the Company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update them except as required by law.

Contact

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

[email protected] 

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

[email protected] 

SOURCE Lakewood-Amedex Biotherapeutics Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900567
Press Eligible
Yes
Press Eligible Reason
Biotechnology company announces preclinical antimicrobial research results and development plans.
Source Name
Unknown Company
Original Summary

<p>Intravesical administration of the Bisphosphocin® Nu-8 to rodents infected with E. coli demonstrated up to 97% inhibition of E. coli growth compared to no effect in a vehicle control group. SARASOTA, Fla., Oct. 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT,...</p>

Image URL
https://mmx.prnewswire.com/media/MS606836/Lakewood-Amedex-Biotherapeutics-Logo.jpg?id=OA2990056&p=facebook
Content Hash (SHA-256, erste 32 hex)
c193091f77977ac024c74ec980f8a6a4
Simple Mining Acquires Sphere 3D Bitcoin Mining Site in Iowa, Growing Platform to Nearly 160 MW
Image File
Original HTML

Simple Mining Acquires Sphere 3D Bitcoin Mining Site in Iowa, Growing Platform to Nearly 160 MW

Approximately 8 MW facility supports about 2,200 latest-generation miners

CEDAR FALLS, Iowa, Oct. 7, 2026 /PRNewswire/ -- Simple Mining, a Bitcoin mining hosting and infrastructure company, today announced it has acquired an approximately 8 MW Bitcoin mining facility in Iowa from Sphere 3D Corp. (NASDAQ: ANY).

The facility supports approximately 2,200 latest-generation miners, bringing Simple Mining's Iowa platform to nearly 160 MW. The acquisition expands the owned hosting capacity available to Simple Mining's customers, who purchase and host miners on the company's infrastructure.

This site joins the network of facilities Simple Mining owns and operates across Iowa, and will run under the same model as the rest of the platform, with machine sales, hosting, and repair handled in-house by Simple Mining's own team. Customers at the site will have access to the company's dedicated ASIC repair operation and the same support team that serves the rest of the platform.

The deal continues a period of rapid growth for Simple Mining, which has been steadily expanding its Iowa platform. Simple Mining is hiring across site operations, engineering, and sales to support that growth.

"This acquisition adds fully energized, high-performing capacity to our platform from day one," said Adam Haynes, CEO of Simple Mining. "It brings another site under the same operating standard we deliver to every customer."

"Our customers want more room to grow on infrastructure we own and operate, and this site delivers exactly that," said Nick Garland, Chief Operating Officer of Simple Mining. "Every megawatt we add in Iowa is capacity our customers can put to work."

About Simple Mining

Simple Mining is a Bitcoin mining infrastructure company headquartered in Cedar Falls, Iowa, focused on the sale, hosting, and repair of Bitcoin miners. With nearly 160 MW of capacity across Iowa and more than 40,000 machines under management, Simple Mining helps investors mine Bitcoin from anywhere in the world. Learn more at simplemining.io

SOURCE Simple Mining

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302900603
Press Eligible
Yes
Press Eligible Reason
Bitcoin mining infrastructure acquisition expands the company’s hosting capacity.
Source Name
Unknown Company
Original Summary

<p>Approximately 8 MW facility supports about 2,200 latest-generation miners CEDAR FALLS, Iowa, Oct. 7, 2026 /PRNewswire/ -- Simple Mining, a Bitcoin mining hosting and infrastructure company, today announced it has acquired an approximately 8 MW Bitcoin mining facility in Iowa from Sphere...</p>

Image URL
https://mmx.prnewswire.com/media/MS2003586/Simple-Mining-Iowa-platform-photo.jpg?id=OA2990580&p=facebook
Content Hash (SHA-256, erste 32 hex)
8f146018c15b7730355ca710a151a43e
X-Bow Awarded Nearly $70M to Develop Advanced Booster for Future Navy Missiles
Image File
Original HTML

X-Bow Awarded Nearly $70M to Develop Advanced Booster for Future Navy Missiles

Award funds development, qualification, and tooling for a high-rate production line in Texas

ALBUQUERQUE, N.M., Oct. 7, 2026 /PRNewswire/ -- X-Bow Systems Inc (X-Bow®), a U.S. non-traditional manufacturer of solid rocket motors (SRMs), today announced it has been awarded a prototype agreement worth nearly $70 million to develop and qualify a solid rocket motor booster for a key U.S. Navy next-generation weapon, a program central to addressing future surface warfare challenges.

The award is the latest of six new propulsion programs X-Bow has been selected for in 2026, spanning the Navy, Army, and the Missile Defense Agency. This builds on the company's recently completed first major production contract, which delivered more than 2,100 combat-ready rocket motors—a tangible demonstration of the 'production is deterrence' capacity the nation needs.

"To be the Arsenal of Freedom, we must first break the decades-old bottleneck in solid rocket motor production," said Jason Hundley, Founder and CEO of X-Bow Systems. "This award is a clear signal the Pentagon is investing in advanced manufacturing to solve that problem, and we are ready to deliver the affordable, mass-producible propulsion our nation needs."

Administered by U.S. Army Contracting Command – Rock Island, the agreement has a total potential value of $69.7 million. It comprises a $50.4 million Phase 1 development effort and a $19.3 million Phase 2 qualification option, with $50 million obligated at award to incrementally fund the 12-month Phase 1 effort.

The program replaces single-purpose interceptors with a common architecture, including variants that pack more interceptors into each launch system. The Navy plans to field an initial capability in early FY 2031.

X-Bow will execute the program across its advanced manufacturing and R&D facilities in California, New Mexico, and Texas. The agreement funds rate tooling for a production line of up to 500 motors per year at the company's Luling, Texas, site, leveraging X-Bow's Modular Motor Architecture.

About X-Bow Systems

X-Bow is solving the nation's munitions crisis by breaking the 50-year bottleneck in solid rocket motor (SRM) production. The company leverages its proprietary additive manufacturing to produce affordable, scalable SRMs that power a new generation of missiles, interceptors, and space launch vehicles. Reflecting strong demand, the company's revenue and backlog have more than doubled since 2023. Backed by prominent aerospace and venture capital investors, the company is headquartered in Albuquerque, New Mexico, with advanced manufacturing and test sites across the country. For more information, visit www.XBowSystems.com.

SOURCE X-Bow Systems

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302901101
Press Eligible
Yes
Press Eligible Reason
Company contract award and advanced manufacturing program for missile propulsion.
Source Name
Unknown Company
Original Summary

<p>Award funds development, qualification, and tooling for a high-rate production line in Texas ALBUQUERQUE, N.M., Oct. 7, 2026 /PRNewswire/ -- X-Bow Systems Inc (X-Bow®), a U.S. non-traditional manufacturer of solid rocket motors (SRMs), today announced it has been awarded a prototype...</p>

Image URL
https://mmx.prnewswire.com/media/MS2004089/X-Bow-Systems-Image.jpg?id=OA2992035&p=facebook
Content Hash (SHA-256, erste 32 hex)
91619c42c79d2dd86b102d4ed13271d4